Helen Tayton-Martin, Ph.D., M.B.A.
About Helen Tayton-Martin, Ph.D., M.B.A.
Helen Tayton-Martin, Ph.D., M.B.A., is the Chief Business & Strategy Officer at Adaptimmune, overseeing strategic and commercial opportunities, including significant partnerships with major pharmaceutical companies.
Helen Tayton-Martin, Ph.D., M.B.A. - Chief Business & Strategy Officer
Helen Tayton-Martin, Ph.D., M.B.A., currently holds the position of Chief Business & Strategy Officer. In this role, she is responsible for optimizing strategic and commercial opportunities for Adaptimmune's assets. Dr. Tayton-Martin leads business development, competitive intelligence, and alliance management, playing a critical role in driving the company's growth and strategic initiatives.
Educational Background in Molecular Immunology and Business
Helen Tayton-Martin holds a Ph.D. in molecular immunology from the University of Bristol, U.K., demonstrating her expertise in the field. She furthered her education by earning an M.B.A. from London Business School, equipping her with a strong foundation in business administration and strategic management.
Career History: Chief Operating Officer and Chief Business Officer
Helen Tayton-Martin served as the Chief Operating Officer of Adaptimmune from 2008, before taking on the role of Chief Business Officer in 2017. During her tenure, she oversaw the company's transition from five to 300 staff, contributed to its transatlantic growth, and facilitated multiple clinical, academic, and commercial collaborations. Her efforts were pivotal in guiding the company through private and public financing, culminating in its Nasdaq IPO.
Strategic Partnerships and Business Development
In her capacity as Chief Business & Strategy Officer, Helen Tayton-Martin's role includes all aspects of pipeline and technology assessment, strategic portfolio analysis, and partnerships. She has been instrumental in forming strategic collaborations with industry giants such as Astellas, Genentech (a member of the Roche Group), and GlaxoSmithKline, ensuring that Adaptimmune remains a leader in its field.
Non-Executive Director Roles and Company Formation
Helen Tayton-Martin previously served as a non-executive director of Trillium Therapeutics Inc. from October 2017 until its acquisition by Pfizer Inc. in November 2021. Additionally, she co-founded Adaptimmune from the former company, Avidex Limited, where she was responsible for business development of the soluble TCR program in cancer and HIV from 2005 to 2008.